17,261 trials
Post COVID-19 Condition · Long COVID
Primary: Change From Baseline to Week 13 in PROMIS Fatigue Score (T-Score) — 69.9; 69.4; -25.4; -25.8 T-Score — p=0.9851
Solid Tumors
Primary: Determine the RPII Dose of NC-6004 in Combination With Gemcitabine — 0; 0; 0; 0 Participants
Chronic GVHD
Primary: Fraction of Participants With an Overall Response Rate (Complete Response [CR] + Partial Response [PR]) Reported With an 80% Confidence Interval at 6 Months — 0; 0.1667…
Soft Tissue Injury
Primary: Tenderness (Algometry) Over the Initial 72 Hours — 1213.88; 1041.04; 850.79 Nxh/cm^2 — p=0.0221
Influenza A H1N1
Primary: To Evaluate Viral Load by Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) of SAB-176 When Compared to Placebo — 273.05; 91.98 Log10 copies*hour/mL
Melanoma · Carcinoma, Non-Small- Cell Lung
Primary: Confirmed Objective Response Rate (cORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Per Investigator Assessment — 0; 5; 44; 25…
Neoplasms
Primary: Overall Response Rate — 10.3; 0; 0; 8.6 percentage of participants
Obesity
Primary: Relative Change in Body Weight (%) — -0.33; 0.38 Percentage of body weight change
Diffuse Intrinsic Pontine Glioma · Glioma · Diffuse Midline Glioma, H3 K27M-Mutant
Primary: Percentage of Participants With Adverse Events (AE) Related to Treatment — 5.26; 0; 0; 21.0 percentage of participants
Detrusor Underactivity · Overactive Bladder
Primary: Changes in the Mean BCI for Male From Baseline to Week 12 — 64.604; 61.339; 75.156; 60.513 Score on a scale — p=<0.001
Type 2 Diabetes Mellitus · Chronic Kidney Diseases
Primary: The Primary Endpoint Was Percentage Change in UACR of Cotadutide at Different Dose Levels Compared to Placebo After 14 Weeks — -10.96; -40.47; -44.60; 4.60 Percentage…
Type 1 Diabetes Mellitus
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period — 28; 13; 4; 1 Participants
Clostridium Difficile Infection
Primary: Segment 2A: Clinical Cure (CC) of Clostridioides Difficile Infection (CDI) Per Protocol (PP)/Modified Intent-to-Treat (mITT) Population — 10; 0 Participants
Food Allergy · Anaphylaxis Food
Primary: Number of Doses of Ibrutinib for Maximal Suppression of Skin Prick Test Size to Foods — 2 doses — p=<0.0001
Dengue
Primary: Percentage of Study Participants With Each Solicited, Related Adverse Event Types of Any Severity. — 1; 0; 1; 0 Participants